Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study.

Parida S, Swain TR, Routray SN, Maiti R.

J Clin Diagn Res. 2017 Feb;11(2):FC04-FC09. doi: 10.7860/JCDR/2017/23741.9427. Epub 2017 Feb 1.

2.

Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis.

Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ.

Sci Rep. 2017 Jan 10;7:39982. doi: 10.1038/srep39982.

3.

Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study.

Millán Núñez-Cortés J, Cases Amenós A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC, Pintó Sala X, Serrano Cumplido A.

Am J Cardiovasc Drugs. 2017 Apr;17(2):135-142. doi: 10.1007/s40256-016-0197-9.

4.

Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database.

Lee J, Noh Y, Shin S, Lim HS, Park RW, Bae SK, Oh E, Kim GJ, Kim JH, Lee S.

Ther Clin Risk Manag. 2016 Oct 11;12:1533-1543. eCollection 2016.

5.

Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials.

Rahal AJ, ElMallah AI, Poushuju RJ, Itani R.

Saudi Med J. 2016 Oct;37(10):1051-60. doi: 10.15537/smj.2016.10.16078.

6.

Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients.

Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ 3rd, Caraballo PJ.

J Gen Intern Med. 2016 May;31(5):502-8. doi: 10.1007/s11606-015-3583-0. Epub 2016 Feb 5.

7.

Statin use and risk of diabetes mellitus.

Chogtu B, Magazine R, Bairy KL.

World J Diabetes. 2015 Mar 15;6(2):352-7. doi: 10.4239/wjd.v6.i2.352. Review.

8.

Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.

Ramadan WH, Kabbara WK.

Vasc Health Risk Manag. 2015 Feb 11;11:125-32. doi: 10.2147/VHRM.S79198. eCollection 2015. Review.

9.

Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial.

Wiersma JJ, Dijksman LM, Ten Holt WL, Radder JM, Verberne HJ, van Eck-Smit BL, Trip MD, Cherpanath TG, Dunselman PH, Tijssen JG, Piek JJ.

Neth Heart J. 2006 Dec;14(12):409-416.

10.

Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.

de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E.

PLoS One. 2014 Nov 5;9(11):e111247. doi: 10.1371/journal.pone.0111247. eCollection 2014.

11.

Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats.

Xu L, Zang P, Feng B, Qian Q.

Diabetol Metab Syndr. 2014 Sep 23;6(1):102. doi: 10.1186/1758-5996-6-102. eCollection 2014.

12.

Statin induced diabetes and its clinical implications.

Aiman U, Najmi A, Khan RA.

J Pharmacol Pharmacother. 2014 Jul;5(3):181-5. doi: 10.4103/0976-500X.136097. Review.

13.
15.

Diabetogenic effect of statins: a double-edged sword?

Yoon JS, Lee HW.

Diabetes Metab J. 2013 Dec;37(6):415-22. doi: 10.4093/dmj.2013.37.6.415.

16.

Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.

Chang YH, Hsieh MC, Wang CY, Lin KC, Lee YJ.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):157-70. doi: 10.1900/RDS.2013.10.157. Epub 2013 Aug 10. Review.

18.

Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.

Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM.

Am Heart J. 2013 Aug;166(2):199-207.e15. doi: 10.1016/j.ahj.2013.03.018. Epub 2013 May 3.

19.

Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension.

Kim W, Hong MJ, Woo JS, Kang WY, Hwang SH, Kim W.

Chonnam Med J. 2013 Apr;49(1):31-7. doi: 10.4068/cmj.2013.49.1.31. Epub 2013 Apr 25.

20.

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus.

Feher M, Greener M, Munro N.

Diabetes Metab Syndr Obes. 2013;6:11-5. doi: 10.2147/DMSO.S35053. Epub 2013 Jan 10.

Supplemental Content

Support Center